11 September 2018
Visiongain has launched a new pharma report: In-Vitro Diagnostics World Market Report : Point of Care, Clinical Chemistry, Immunochemistry, Haematology, Microbiology, Molecular Diagnostics, Flow Cytometry, Infectious Diseases, Diabetes, Cardiology, Autoimmune Diseases, Renal Diseases, Pharmacogenomics, HIV/AIDS, Reagent & Kits, Instruments, Data Management Software & Services, Hospitals, Laboratories, Home Care Testing, Research Institutes, Blood Glucose Testing, Infectious Disease Testing, Rapid Coagulation Testing, Cholesterol Testing, Pregnancy Testing, Basic Metabolic Panel, Electrolyte Panel, Liver Profile, Lipid Profile, Thyroid Function Test, ELISA, Immuno-PCR, Rapid Test, Western Blot, Enzyme linked Immunospot Assay
In vitro diagnostic (IVD) tests are medical assays performed on bodily fluids or tissues, as a diagnostic tool for a range of clinical disorders. The information obtained from such tests may act as a key factor in the decision making of a patient’s particular treatment plan. Examples of tests currently performed today include measuring the concentrations of various chemical and biochemical components, counting cells, measuring physical properties of the sample, microscopic examination of cells and other structures or preparing biological cultures. The generally positive outlook for the IVD industry has led to a large amount of merger and acquisition activity over previous years. These market trends are set to continue as the larger industry leaders look to consolidate power in an industry which is set to be worth $78.4bn by 2020.
The lead analyst of the report commented "Strengths in the IVD market primarily results from patient demographics. The rise in the global aging population will bear witness to an increasing incidence of age-related diseases, such as cardiovascular disease and cancer. This in turn has fuelled demand for advanced diagnostic testing equipment, capable of providing accurate clinical diagnoses, which allows for earlier medical intervention.
In addition, technological innovations in this field have introduced increasingly miniaturised and automated devices into the marketplace, which has given rise to a new range of condition-specific tests. Furthermore, continued research and development in IVD has allowed the discovery of new biomarkers, which has expanded the clinical application of IVD testing."
Leading companies featured in the report include Abbott Diagnostics, Agilent Technologies, Becton, Dickinson and Company (BD), BioMerieux, Bio-Rad, Danaher Corporation, DiaSorin Diagnostics s.p.a, Roche Diagnostics, Siemens Diagnostics, Sysmex Corporation
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.
11 May 2021
Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.
11 May 2021
The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.
06 May 2021
Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.